Evidence map›Paper›PMID 41155658›Full record

ReviewPharmaceuticals (Basel, Switzerland)2025

From Ototoxicity to Otoprotection: Mechanism and Protective Strategies in Cisplatin Therapy.

Andreea Iațentiuc, Sebastian Romică Cozma, Otilia Elena Frăsinariu, Ingrith Crenguța Miron, Iustin Mihai Iațentiuc, Lucia Corina Dima-Cozma, Raluca Olariu, Anca Postolache, Ana-Maria Laura Buga, Alexandru Stingheriu and 2 more

Erratum issuedAbstract readReview
In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Andreea IațentiucDepartment of Mother and Child Medicine, University of Medicine and Pharmacy Grigore T. Popa, 700115 Iași, Romania.
Sebastian Romică CozmaSurgery II Department, ENT Discipline, University of Medicine and Pharmacy Grigore T. Popa, 700115 Iasi, Romania.ORCID 0000-0002-3768-6232
Otilia Elena FrăsinariuDepartment of Mother and Child Medicine, University of Medicine and Pharmacy Grigore T. Popa, 700115 Iași, Romania.ORCID 0000-0002-5836-1517
Ingrith Crenguța MironDepartment of Mother and Child Medicine, University of Medicine and Pharmacy Grigore T. Popa, 700115 Iași, Romania.
Iustin Mihai IațentiucDoctoral School, University of Medicine and Pharmacy Grigore T. Popa, 700115 Iasi, Romania.
Lucia Corina Dima-CozmaDepartment of Medical Specialties I, University of Medicine and Pharmacy Grigore T. Popa, 700115 Iași, Romania.
Raluca OlariuSurgery II Department, ENT Discipline, University of Medicine and Pharmacy Grigore T. Popa, 700115 Iasi, Romania.ORCID 0009-0001-1221-5397
Anca PostolacheDepartment of Mother and Child Medicine, University of Medicine and Pharmacy Grigore T. Popa, 700115 Iași, Romania.ORCID 0000-0002-1519-9898
Ana-Maria Laura BugaDepartment of Mother and Child Medicine, University of Medicine and Pharmacy Grigore T. Popa, 700115 Iași, Romania.
Alexandru StingheriuDoctoral School, University of Medicine and Pharmacy Grigore T. Popa, 700115 Iasi, Romania.
Edilene BoéchatDepartment of Audiology, Speech Pathology and Physiotherapy, Faculty of Human and Health Sciences, Pontifical University of São Paulo, São Paul 01246-904, Brazil.
Oana Roxana Bitere-PopaBiomedical Sciences Department, Faculty of Medical Bioengineering, University of Medicine and Pharmacy Grigore T. Popa, 700115 Iasi, Romania.ORCID 0009-0003-9520-7695

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although cisplatin plays a vital role in chemotherapy protocols, its impact on hearing should not be overlooked. The ototoxic effects of cisplatin can lead to hearing loss. Childhood hearing loss can significantly impact various aspects of development. Understanding the mechanism of cisplatin-induced ototoxicity is crucial due to its high level of complexity. The process involves multiple interconnected steps, ranging from cisplatin absorption to its interaction with the cellular antioxidant defense system, nuclear DNA, mitochondria, and the cytokine cascade. Each of these interactions contributes to the overall pathophysiology of ototoxicity and is closely interrelated. Based on these, various hypotheses and conclusions were outlined, and we tried to analyze them as broadly as possible. Knowledge of these mechanisms has given rise to promising avenues and otoprotection strategies to combat ototoxicity. Although there is only one drug approved by the FDA (Food and Drug Administration), there are numerous drugs that target the mechanisms presented, but that need more evidence to be able to be used safely. In addition to these, the role of the multidisciplinary team should not be neglected and protocols should be established for periodic follow-up of patients treated with cisplatin to prevent hearing loss. This narrative review aims to point out all the aspects presented, based on the analysis of the literature and the conclusions drawn over time. We have selected the articles of interest and analyzed the studies that have obtained promising results to bring an overview of how cisplatin acts at the cochlear level, what can be done to combat these mechanisms, what solutions exist now and how we can prevent hearing loss.

Indexed as

cisplatinmultidisciplinary teamotoprotectionototoxicity

Identifiers

PMID41155658
PMCPMC12566770

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.